Emily  Zabor,  PhD

Emily Zabor, PhD

Assistant Staff

Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195

 

My primary research interests relate to statistical methods for retrospective data analyses and epidemiologic studies, and clinical trial design. My dissertation research focused on development of a statistical method to identify biologic subtypes of disease that differ with respect to risk factors for the disease, a concept known as etiologic heterogeneity. This methodology can be used to identify subtypes of disease with particular risk factors, which could then be used in screening efforts, for development of targeted therapies, or to improve power when planning future epidemiologic studies of the disease. I am currently working to develop novel statistical methods for early stage oncology trials, with a focus on trials for treatments that target a common biomarker across a variety of disease histologies, known as basket trials. Finally, I have a special interest in the particular challenges of survival analyses when data are from electronic health records.


A comprehensive list of my publications can be found on my Google Scholar page. Selected methodologic and collaborative publications in several areas are detailed below.

Selected methodologic publications:

  1. Zabor, E. C., Kaizer, A. M., & Hobbs, B. P. (2020). Randomized Controlled Trials. Chest, 158(1s), S79-s87. https://doi:10.1016/j.chest.2020.03.013
  2. Zabor, E. C. (2019). riskclustr: Functions to Study Etiologic Heterogeneity. Journal of Open Source Software, 4(35), 1269. https://doi.org/10.21105/joss.01269  
  3. Zabor, E. C., Coit, D., Gershenwald, J. E., McMasters, K. M., Michaelson, J. S., Stromberg, A. J., & Panageas, K. S. (2018). Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. Ann Surg Oncol, 25(8), 2172-2177. https://doi.org/10.1245/s10434-018-6370-4
  4. Zabor, E. C., & Begg, C. B. (2017). A comparison of statistical methods for the study of etiologic heterogeneity. Stat Med, 36(25), 4050-4060. https://doi.org/10.1002/sim.7405 Zabor, E. C., Heller, G., Schwartz, L. H., Chapman, P. B. (2016). Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. Clin Cancer Res, 22(6), 1341-1347. https://doi.org/10.1158/1078-0432.CCR-15-1441
  5. Zabor, E. C., Gonen, M., Chapman, P. B., Panageas, K. S. (2013). Dynamic prognostication using conditional survival estimates. Cancer, 119(20), 3589-3592. https://doi.org/10.1002/cncr.28273

Recent collaborative publications:

  1. Zabor, E. C., Radivoyevitch, T., Singh, A. D., Kilic, E., de Klein, J., Kalirai, H., & Coupland, S. E. (2020). Conditional Survival in Uveal Melanoma. Ophthalmol Retina. https://doi:10.1016/j.oret.2020.09.015
  2. Brierley, C. K., Zabor, E. C., Komrokji, R. S., DeZern, A. E., Roboz, G. J., Brunner, A. M., Stone, R. M., Sekeres, M. A., & Steensma, D. P. (2020). Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer, 126(21), 4735-4743. https://doi:10.1002/cncr.33105
  3. Bilani, N., Zabor, E. C., Elson, L., Elimimian, E. B., & Nahleh, Z. (2020). Breast Cancer in the United States: A Cross-Sectional Overview. J Cancer Epidemiol, 2020, 6387378. https://doi:10.1155/2020/6387378


No news currently found.